HCPs, what do you view as the greatest barrier to the use of belantamab mafodotin combinations in clinical practice? #MultipleMyeloma #myeloma #mmsm #MedEd

New publication 📝 SWOG S1702 phase II results, published in Blood, show isatuximab achieved high hematologic response rates (77.1%) with organ responses and a manageable safety profile in patients with R/R AL amyloidosis. Learn more: https://t.co/1ZQsKbd440 #mmsm #myeloma

Would you like to bookmark content, select your specific areas of interest, and view content recommended for you? Enter your email address to create an account: https://t.co/nnvsEhXItl #mmsm

⭐ Multiple Myeloma Hub spotlight: Latest data from CC-92480-MM-002 ⭐ During #IMS25, Albert Oriol presented the latest data and analysis from CC-92480-MM-002, focusing on the efficacy of MeziVd and MeziKd by prior LOT in RRMM. #MultipleMyeloma #myeloma #mmsm #MedEd

New publication 📝 Phase II results from LYNX, published in Leukemia & Lymphoma, show no significant difference in ≥VGPR rates with Dara retreatment in RRMM with prior Dara exposure (DaraKd, 45.5%; Kd, 40.9%; p = 0.68). Learn more: https://t.co/NiAI9nCkLX #MultipleMyeloma

⭐ Multiple Myeloma Hub spotlight: Iberdomide for the treatment of transplant ineligible/deferred NDMM ⭐ Updates from #IMS25 included latest data from GEM-IBERDARAX and CC-220-MM-001 of iberdomide in combination with Dd. #MultipleMyeloma #myeloma #mmsm

Results from part 1, dose level G of the MagnetisMM-6 study informed the recommended phase III dose of elranatamab (76 mg SC Q4W) for part 2 of the study. Catch up on the initial results with our spotlight here. https://t.co/NmxLNkEwAh #MultipleMyeloma #myeloma #mmsm

Early clinical data with CELMoDs demonstrate antimyeloma activity in patients with both newly diagnosed and relapsed or heavily pretreated #MultipleMyeloma. HCPs, catch up on the latest updates from the 22nd IMS Annual Meeting on mezigdomide and iberdomide here:

Dose modifications with belantamab mafodotin can preserve efficacy while reducing ocular toxicity, allowing patients to stay on treatment longer. Watch the full video here: https://t.co/daFpMEfHhl #MultipleMyeloma #myeloma #mmsm #MedEd @DrRakeshPopat @ucl

New publication 📝 Results from MagnestisMM-3, published in @Hemasphere_EHA, found switching from elranatamab QW to Q2W led to improvement in HRQoL in patients with RRMM, independent of prior BCMA therapies exposure. Learn more: https://t.co/eHpkjvJTHu #mmsm #myeloma

New expert insights 📝 Paul Richardson highlights high MRD negativity (63% at 10−5, 47% at 10−6) in the phase III MIDAS trial of Isa-KRd in patients with NDMM, with a manageable safety profile. Learn more: https://t.co/ah4gJhxeDZ #MultipleMyeloma #myeloma #MedNews #MedEd

🚨 NEWS 🚨 @US_FDA approves belantamab mafodotin in combination with bortezomib + dexamethasone for the treatment of relapsed/refractory #MultipleMyeloma and ≥2 prior therapies, including a PI and an IMiD. Read more: https://t.co/a5N9Dbmv1O #myeloma #mmsm #MedNews #MedEd

Ocular toxicity associated with belantamab mafodotin can be manageable with dose modifications, supportive care, and regular monitoring. Watch out for our latest interview, with @DrRakeshPopat @ucl https://t.co/daFpMEfHhl #MultipleMyeloma #myeloma #mmsm #MedEd

New podcast 📝 Paul Richardson discusses findings from the phase III MIDAS trial of Isa-KRd in patients with NDMM, which support tailored therapy with risk-adapted, MRD-guided treatment. Learn more: https://t.co/AQ2UB2kUxY #MultipleMyeloma #myeloma #MedNews #MedEd

New podcast | @DrRakeshPopat @UCL discusses clinical experience with belantamab mafodotin, with a focus on management strategies for ocular toxicity. Listen here: https://t.co/GzTUTvPnUy #MultipleMyeloma #myeloma #mmsm #MedEd

The Multiple Myeloma Hub spoke with @DrRakeshPopat @UCL. We asked about clinical experience with belantamab mafodotin, with a focus on management strategies for ocular toxicity. https://t.co/daFpMEfHhl #MultipleMyeloma #myeloma #mmsm #MedEd

HCPs, answer our poll below! Which of the following reflects your thoughts about the feasibility of nursing staff preparing oncology treatments at the bedside at your clinical practice site, as opposed to in the pharmacy? #MultipleMyeloma #myeloma #mmsm #MedEd

CELMoDs represent a new class of therapy in multiple myeloma, with the potential to overcome immune exhaustion and target high-risk disease, including patients who have previously received BCMA-directed therapies. Watch the full video here: https://t.co/0qZqrgicrX

The Multiple #Myeloma Hub newsletter provides healthcare professionals with up-to-date global advances in #MultipleMyeloma relating to its classification, diagnosis, treatment, and management. View a previous newsletter: https://t.co/XXTySoBtqM #mmsm

In our latest podcast, Paul Richardson @DanaFarber discussed the latest clinical trial data and applications for CELMoD agents across the treatment paradigm for #MultipleMyeloma. Listen here: https://t.co/hXT4cxEdYn #mmsm #myeloma #MedEd